Belinostat: Phase I/II data
The open-label, European Phase I/II PXD101-CLN-15 trial in 41 patients with AML not suitable for intensive induction therapy showed that belinostat plus idarubicin produced 5 complete remissions (CRs) and 2 partial remissions (PRs) in patients with low/intermediate-risk cytogenetic aberrations (n=25) and no CRs and 2 PRs in high-risk patients (n=16). Patients received idarubicin plus either a 30-minute IV infusion of 1,000 mg/m 2 belinostat on days 1-5 of a 21-day cycle or continuous IV infusion of 25-1,000 mg/m 2 belinostat on days 1-2 of a 14-day cycle. The objective response rate (ORR) was 17% in the 30-minute IV infusion group and 31% in the continuous IV infusion group. Data will be presented at the European Society for Medical Oncology meeting in Vienna in October. ...